Skip to main content

Psoriatic arthritis

      PsA and Brain Fog
      PsA Predictors
      The multimillion dollar question for inflammatory arthritis prescriptions is: which drug should I use next?
      Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.
      Rheumatology Roundup
      Specialized Biomarkers in PsA
      Psoriatic Arthritis Imaging

      Dr. Arthur Kavanaugh talks about imaging in psoriatic arthritis at #ACR25

      https://t.co/l6M

      Dr. John Cush RheumNow

      1 month 1 week ago
      Psoriatic Arthritis Imaging Dr. Arthur Kavanaugh talks about imaging in psoriatic arthritis at #ACR25 https://t.co/l6MKTgEJXu https://t.co/sKhoQWCPli
      GLP-1 Receptor Agonists in PsA: Mortality and MACE https://t.co/GtTGHY7j5g

      @synovialjoints discussed TriNetX data bas

      Nouf Al hemmadi NoufAhmedAlham2

      1 month 1 week ago
      GLP-1 Receptor Agonists in PsA: Mortality and MACE https://t.co/GtTGHY7j5g @synovialjoints discussed TriNetX data base looking at GLP-1 medications effect on MACE in PsA patients. @RheumNow #ACR25
      What happens if you have #axSpA & concomitant #FM?

      Pts with both have less TNFi retention,
      -residual pain may lead

      Janet Pope Janetbirdope

      1 month 1 week ago
      What happens if you have #axSpA & concomitant #FM? Pts with both have less TNFi retention, -residual pain may lead to d/c Rx. Need to determine if axSpA pt has #fibromyalgia as there may not be objective findings if no peripheral arthritis in axSpA. #ACR25 @RheumNow abst#534
      A new player is entering the IL-23 arena — and it’s a tablet! Icotrokinra (ICO), a first-in-class peptide that binds and blocks the interleukin-23 receptor (IL-23R), is showing encouraging efficacy and safety across a range of psoriasis (PSO) and psoriatic disease (PsD) studies.
      ×